Vibrio choleraelipopolysaccharide loaded chitosan nanoparticle could save life by induction of specific immunoglobulin isotype
Source abstract
Abstract
The lipopolysaccharide (LPS) of Vibrio cholerae (V. cholerae) plays an important role in cholera disease and the induction of primary protection. In this study, we evaluate mice humoral immune response in intranasal and intraperitoneal administrated V. cholerae LPS. The results showed that the intranasal administration of LPS-chitosan nanoparticle induced the high level of antibodies compared to intraperitoneal injection of antigen without chitosan (P < .001). These results indicated that intranasal and intraperitoneal administration of LPS has been able to induce the high level of antibodies both in the sera and lavage fluid and confirmed our strategy for using intranasal administration of antigen.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Vibrio bacteria research studies · Aquaculture disease management and microbiota · Escherichia coli research studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;
Department of Microbiology, Faculty of Biological Science, Islamic Azad University, North Tehran Branch, Tehran, Iran;
Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran;
Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
Funding
Molecular Biology Research Center, Baqiyatallah University of Medical Sciences
References (34)
Show source-provided references
1. Abdollahi A · Iran J Microbiol · 2016 · 8 · 193
2. 10.1007/s11259-015-9645-210.1007/s11259-015-9645-2 ↗
3. Ahmadi K · Med J Islam Repub Iran (MJIRI) · 2006 · 20 · 52
4. 10.1080/21691401.2016.123311110.1080/21691401.2016.1233111 ↗
5. 10.1080/21691401.2016.123311110.1080/21691401.2016.1233111 ↗
6. 10.3109/21691401.2014.96619310.3109/21691401.2014.966193 ↗
7. 10.1128/CVI.00526-1510.1128/CVI.00526-15 ↗
8. 10.1111/jam.1204310.1111/jam.12043 ↗
9. 10.1016/j.bbadis.2005.08.00510.1016/j.bbadis.2005.08.005 ↗
10. 10.1016/j.addr.2006.01.00210.1016/j.addr.2006.01.002 ↗
11. Doavi T · Iran Biomed J · 2016 · 20 · 97
12. Fasihi-Ramandi M · Iran J Allergy Asthma Immunol · 2015 · 14 · 502
13. Fasihi-Ramandi M · Int J Enteric Pathog · 2016 · 4 · e33137
14. 10.3844/ajisp.2014.56.6210.3844/ajisp.2014.56.62 ↗
15. Fournier JM. · Bull Soc Pathol Exot · 1998 · 91 · 412
16. 10.1016/S1773-2247(14)50005-610.1016/S1773-2247(14)50005-6 ↗
17. 10.1371/journal.pone.010852110.1371/journal.pone.0108521 ↗
18. 10.1371/journal.pntd.000307610.1371/journal.pntd.0003076 ↗
19. 10.1128/CVI.00035-1310.1128/CVI.00035-13 ↗
20. 10.1371/journal.pmed.004033610.1371/journal.pmed.0040336 ↗
21. 10.1016/j.ab.2004.12.00110.1016/j.ab.2004.12.001 ↗
22. Mirnejad R · Iran J Biotechnol · 2014 · 12 · e1012
23. 10.1371/journal.pone.008181710.1371/journal.pone.0081817 ↗
24. Onischenko GG · Zh Mikrobiol Epidemiol Immunobiol · 2016 · 1 · 8910.36233/0372-9311-2016-1-89-101 ↗
25. 10.1111/j.1600-065X.2010.00970.x10.1111/j.1600-065X.2010.00970.x ↗
26. 10.1128/CVI.00037-1210.1128/CVI.00037-12 ↗
27. Pawlowska K · Med Dosw Mikrobiol · 2004 · 56 · 293
28. 10.1128/CVI.00347-1310.1128/CVI.00347-13 ↗
29. Rezaei Mokarram A · Arch Razi Inst · 2016 · 61 · 13
30. 10.1016/j.vaccine.2016.02.02010.1016/j.vaccine.2016.02.020 ↗
31. 10.1371/journal.pntd.000388110.1371/journal.pntd.0003881 ↗
32. Skidmore BJ · J Immunol · 1975 · 114 · 77010.4049/jimmunol.114.2_Part_2.770 ↗
33. 10.3109/21691401.2015.111541110.3109/21691401.2015.1115411 ↗
34. 10.4269/ajtmh.13-049810.4269/ajtmh.13-0498 ↗